PET/CT today: System and its impact on cancer diagnosis

Annals of Nuclear Medicine

Volumn 20, Issue 4, 2006, Pages 255-267

  Tsukamoto, Eriko ^a   Ochi, Shinji ^a  

^a Medical Cooperation Teishinkai Central CI Clinic   (Japan)

Author keywords

18F FDG; Positron emission tomography; Radionuclide imaging; Tomography scanners, X ray computed

Indexed keywords

ARTIFACT; CANCER; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLICULAR LYMPHOMA; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; OVARY CANCER; PATIENT POSITIONING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ATTENUATION; RADIODIAGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR RECURRENCE;

HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745835749     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF02984642     Document Type: Review

References (100)

1. Frazee D. Positron emission tomography: a technology assessment of PET imaging - past, present, and future. Radiol Manage 2004; 26: 38-43.
2. 18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection. Eur J Nucl Med 1982; 7: 294-297.
3. 18FDG) for medical use. Radioisotopes 1982; 31: 11-15.
4. Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using " quantitative" parameters of FDG PET images. Clin Nucl Med 1996; 21: 941-949.
5. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997; 12: 92-97.
6. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9: 410-414.
7. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27: 1564-1578.
8. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002; 16: 337-345.
9. 67Ga SPECT in the staging of non-Hodgkin's lymphoma. Ann Nucl Med 2004; 18: 519-526.
10. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-332.
11. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997; 22: 332-337.
12. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613-620.
13. Beyer T, Tellmann L, Nickel I, Pietrzyk U. On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. J Nucl Med 2005; 46: 596-602.
14. von Schulthess GK. Positron emission tomography versus positron emission tomography/computed tomography: from "unclear" to "new- clear" medicine. Mol Imaging Biol 2004; 6: 183-187.
15. Alpert NM, Berdichevsky D, Levin Z, Morris ED, Fischman AJ. Improved methods for image registration. Neuroimage 1996; 3: 10-18.
16. Alyafei S, Inoue T, Zhang H, Ahmed K, Oriuchi N, Sato N, et al. Image Fusion System Using PACS for MRI, CT, and PET Images. Clin Positron Imaging 1999; 2: 137-143.
17. Barra V, Boire JV. A general framework for the fusion of anatomical and functional medical images. Neuroimage 2001; 13: 410-424.
18. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25: 2046-2053.
19. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004; 45 Suppl 1: 4S-14S.
20. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
21. Kluetz P, Villemagne VV, Meltzer C, Chander S, Martinelli M, Townsend D. 20. The Case for PET/CT. Experience at the University of Pittsburgh. Clin Positron Imaging 2000; 3: 174.
22. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, et al. Combined PET/CT Imaging in Oncology. Impact on Patient Management. Clin Positron Imaging 2000; 3: 223-230.
23. Martinelli M, Townsend D, Meltzer C, Villemagne VV. 7. Survey of Results of Whole Body Imaging Using the PET/CT at the University of Pittsburgh Medical Center PET Facility. Clin Positron Imaging 2000; 3: 161.
24. Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med 2005; 46: 2083-2091.
25. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003; 33: 193-204.
26. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002; 75 Spec No: S24-30.
27. 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005; 46: 587-595.
28. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30: 588-596.
29. Sarikaya I, Yeung HW, Erdi Y, Larson SM. Respiratory artefact causing malpositioning of liver dome lesion in right lower lung. Clin Nucl Med 2003; 28: 943-944.
30. Goerres GW, Burger C, Schwitter MR, Heidelberg TN, Seifert B, von Schulthess GK. PET/CT of the abdomen: optimizing the patient breathing pattern. Eur Radiol 2003; 13: 734-739.
31. de Juan R, Seifert B, Berthold T, von Schulthess GK, Goerres GW. Clinical evaluation of a breathing protocol for PET/CT. Eur Radiol 2004; 14: 1118-1123.
32. Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004; 31: 3179-3186.
33. Ay MR, Zaidi H. Development and validation of MCNP4Cbased Monte Carlo simulator for fan- and cone-beam x-ray CT. Phys Med Biol 2005; 50: 4863-4885.
34. Larson SM, Nehmeh SA, Erdi YE, Humm JL. PET/CT in non-small-cell lung cancer: value of respiratory-gated PET. Chang Gung Med J 2005; 28: 306-314.
35. Boucher L, Rodrigue S, Lecomte R, Benard F. Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. J Nucl Med 2004; 45: 214-219.
36. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography - clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003; 33: 228-237.
37. Seemann MD. PET/CT: fundamental principles. Eur J Med Res 2004; 9: 241-246.
38. 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 2002; 29: 346-350.
39. Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von Schulthess GK. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 2002; 29: 922-927.
40. Goerres GW, Ziegler SI, Burger C, Berthold T, Von Schulthess GK, Buck A. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003; 226: 577-584.
41. 18)F]fluoro-D-glucose localization surrounding metallic objects in a PET/CT scanner using CT-based attenuation correction. Mol Imaging Biol 2003; 5: 20-22.
42. Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF, et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 2003; 38: 784-789.
43. Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Jentzen W, Debatin JF, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43: 1339-1342.
44. DiFilippo FP, Brunken RC. Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT? J Nucl Med 2005; 46: 436-443.
45. Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kuhl H, Debatin JF, et al. Positron emission tomography/computed tomography-imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 2004; 6: 188-199.
46. Robinson P, Parkin A. Respiratory motion artefacts on PET/CT. Eur J Nucl Med Mol Imaging 2003; 30: 1712.
47. Papathanassiou D, Becker S, Amir R, Meneroux B, Liehn JC. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source. Eur J Nucl Med Mol Imaging 2005; 32: 1422-1428.
48. Sourbelle K, Kachelriess M, Kalender WA. Reconstruction from truncated projections in CT using adaptive detruncation. Eur Radiol 2005; 15: 1008-1014.
49. Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, et al. Truncation Artifact on PET/CT: Impact on Measurements of Activity Concentration and Assessment of a Correction Algorithm. AJR Am J Roentgenol 2006; 186: 1458-1467.
50. 18F-FDG PET/CT in the Presence of Truncation Artifacts. J Nucl Med 2006; 47: 91-99.
51. Torizuka T, Fisher SJ, Brown RS, Wahl RL. Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 1998; 208: 499-504.
52. Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004; 45 Suppl 1: 25S-35S.
53. Watson CC, Casey ME, Bendriem B, Carney JP, Townsend DW, Eberl S, et al. Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med 2005; 46: 1825-1834.
54. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 2004; 45: 797-801.
55. Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med 2005; 46: 603-607.
56. 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005; 46: 424-428.
57. Wu TH, Chu TC, Huang YH, Chen LK, Mok SP, Lee JK, et al. A positron emission tomography/computed tomography (PET/CT) acquisition protocol for CT radiation dose optimization. Nucl Med Commun 2005; 26: 323-330.
58. Li T, Schreibmann E, Thorndyke B, Tillman G, Boyer A, Koong A, et al. Radiation dose reduction in four-dimensional computed tomography. Med Phys 2005; 32: 3650-3660.
59. Wu TH, Huang YH, Lee JJ, Wang SY, Wang SC, Su CT, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging 2004; 31: 38-43.
60. 18F-FDG PET/CT examinations. J Nucl Med 2005; 46: 608-613.
61. 18F-FDG PET/CT. J Nucl Med 2004; 45 Suppl 1: 56S-65S.
62. 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006; 47: 470-476.
63. Strobel K, Thuerl CM, Hany TF. How much intravenous contrast is needed in FDG-PET/CT? Nuklearmedizin 2005; 44 Suppl 1: S32-37.
64. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005; 32: 1167-1175.
65. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227: 817-824.
66. Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005; 46: 283-291.
67. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-Positive FDG PET Uptake - the Role of PET/CT. Eur Radiol 2006; 16: 1054-1065.
68. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004; 24: 1411-1431.
69. Minotti AJ, Shah L, Keller K. Positron emission tomography/computed tomography fusion imaging in brown adipose tissue. Clin Nucl Med 2004; 29: 5-11.
70. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002; 29: 1393-1398.
71. (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-1796.
72. 18F-FDG PET/CT. J Nucl Med 2003; 44: 1267-1270.
73. Heiba SI, Bernik S, Raphael B, Sandella N, Cholewinski W, Klein P. The distinctive role of positron emission tomography/computed tomography in breast carcinoma with brown adipose tissue 2-fluoro-2-deoxy-D-glucose uptake. Breast J 2005; 11: 457-461.
74. Bar-Shalom R, Gaitini D, Keidar Z, Israel O. Non-malignant FDG uptake in infradiaphragmatic adipose tissue: a new site of physiological tracer biodistribution characterised by PET/CT. Eur J Nucl Med Mol Imaging 2004; 31: 1105-1113.
75. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 2004; 183: 1127-1132.
76. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131-134.
77. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168: 1357-1360.
78. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999; 173: 25-29.
79. 18F-FDG PET/CT. J Nucl Med 2004; 45: 1340-1343.
80. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy - initial experience. Radiology 2006; 238: 970-977.
81. Reinartz P, Wieres FJ, Schneider W, Schur A, Buell U. Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging 2004; 31: 1456-1461.
82. 18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: analysis of 921 lesions. Nuklearmedizin 2004; 43: 210-216.
83. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-4368.
84. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
85. 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med 2004; 45: 2045-2051.
86. Barranger E, Kerrou K, Petegnief Y, David-Montefiore E, Cortez A, Darai E. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol 2005; 96: 241-244.
87. Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumors: detection with dualmodality PET/CT-initial experience. Radiology 2005; 234: 227-234.
88. 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006; 50: 15-22.
89. Metser U, Golan O, Levine CD, Even-Sapir E. Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography? J Comput Assist Tomogr 2005; 29: 554-559.
90. 18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004; 6: 411-416.
91. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237: 1038-1045.
92. Bristow RE. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes: Response to a letter from Dr. Maurie Markman. Gynecol Oncol 2006.
93. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004; 233: 433-440.
94. Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol 2006; 79: 37-43.
95. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62: 893-900.
96. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-863.
97. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1016-1023.
98. Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol 2005; 2: 526-533.
99. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, et al. A prospective study to evaluate the impact of FDGPET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006; 78: 254-261.
100. 18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging 2005; 49: 259-266.